Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

LEUVEN, Belgium, May 13 /PRNewswire-FirstCall/ --

- Regulated Information

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for vascular disease, eye disease and cancer, is today issuing a business update for the three month period ended 31 March 2008.

Prof. Desire Collen, CEO and Chairman of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs are continuing to make the good progress that we had anticipated. During the first three months of 2008, we achieved a number of important clinical milestones that have clearly added further value to our exciting product pipeline. The positive results of our trials with microplasmin are giving us confidence that it has the potential to make a real difference in the field of eye disease. Our exciting new anti-cancer antibody TB-403 has also begun its clinical development. We anticipate seeing further encouraging results across our development pipeline during the remainder of 2008; a year in which we expect to advance ThromboGenics' business significantly."

Financial Update

- In the first quarter of 2008, revenue amounted to EUR 0.1 million, mainly coming from out-licensing. Operating expenses were EUR 3.2 million in the first quarter, the majority of which were due to R&D expenses related to our increasing number of clinical development programs.

- As of 31 March 2008, ThromboGenics had EUR 41.7 million in cash and cash equivalents. This compares to EUR 29.1 million on 31 March, 2007 and EUR 46.1 million on 31 December 2007.

Clinical Update

Highlights

- ThromboGenics completed patient enrolment for its Phase IIb MIVI III trial in the United States for microplasmin in vitrectomy.

Microplasmin is being developed as an adjunct for vitrectomy. A vitrectomy is an increasingly common surgical procedure which is carried out in the treatment of many back of the
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... SAN FRANCISCO, Calif. , May 5, 2015 /PRNewswire/ ... the treatment of cancer, today announced that Sean ... at the Credit Suisse Antibody Day in ... Wednesday, May 6. Dr. McCarthy will present an overview ... immunotherapy and Probody drug conjugate programs. About ...
(Date:5/5/2015)... 2015   Tocagen Inc. , a clinical-stage ... Parkinson , M.D., a venture partner at New ... board of directors of Tocagen. Dr. Parkinson has ... clinical development, including leading clinical activities at Amgen ... the cancer therapeutics Gleevec®, Femara®, Zometa®, Kepivance® and ...
(Date:5/5/2015)... GEA Pharma Systems, G-CON Manufacturing ... of the INTERPHEX Exhibitor Awards for 2015 for ... Continuous, Miniature and Modular (PCMM) platform. PCMM comprises ... processing equipment, smart control systems and PODs (portable, ... inactive ingredients into bulk tablets. , PCMM ...
(Date:5/5/2015)... May 05, 2015 Synedgen Inc. is ... as Regulatory Affairs Manager. , Dr. Nguyen brings to ... juncture for the company as it moves forward in ... over the next two years. Dr. Nguyen will lead ... the regulatory key documents that must be completed in ...
Breaking Biology Technology:Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3Synedgen Announces the Appointment of Regulatory Affairs Manager 2
... ... More Economical Genetic Testing to Facilitate Breed Improvements. Producers, breed associations, livestock researchers ... device that will positively impact the industry’s ability to accelerate breed improvements and ... ...
... ... research databases. , ... January 8, 2010 -- The Society for Clinical Data Management recently published Edit Check Design ... tool for efficiency and data quality., , ,The chapter is a new addition to SCDM’s ...
... Fast-Growing ... partner. , ... Triangle Park, NC (PRWEB) -- TechCFO , one of Inc. Magazine’s 500 Fastest ... and biotechnology companies, today announced the expansion of its Research Triangle Part office with ...
Cached Biology Technology:DNA Genotek Launches New Sample Collection Product to Accelerate Livestock Genetic Testing 2DNA Genotek Launches New Sample Collection Product to Accelerate Livestock Genetic Testing 3DNA Genotek Launches New Sample Collection Product to Accelerate Livestock Genetic Testing 4SCDM Releases Best Practices for Automated Data Cleaning 2TechCFO Continues Research Triangle Park Expansion; Garrison Named New Partner 2
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... study of a space-age, low-gravity training machine used by ... muscles and joints by nearly half when subjects ran ... weight. The new study has implications for both ... returning from knee and hip surgeries, according to Associate ...
... imported foods in the food supply continues to increase, Americans ... disease as some countries may not have the same sanitary ... and Challenges , the latest book in the ASM ... of the greatest weaknesses in the U.S. food safety system ...
... resistance on the rise, tuberculosis is emerging as a bigger ... innovative research at Weill Cornell Medical College suggests that ... one that could be a prime target for drug development. ... protein that,s essential to the defense that M. tuberculosis ...
Cached Biology News:Low-gravity training machine reduces joint, muscle impacts, says CU-Boulder study 2Low-gravity training machine reduces joint, muscle impacts, says CU-Boulder study 3New publication addresses safety of imported foods 2Potential new drug target to fight tuberculosis identified 2Potential new drug target to fight tuberculosis identified 3
... a competitive enzymeimmunoassay (EIA) for the quantitative ... serum or plasma. Corticosterone is the major, ... mice, and in most non-mammalian vertebrates such ... produce both corticosterone and cortisol, in varying ...
... is a complete assay system for the ... human serum or plasma. The assay incorporates ... the IDS 1,25D RIA followed by quantitation ... ready to use reagents, no organic or ...
7G10 anti-Fasciclin III...
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Biology Products: